Control-IQ & Dexcom G7: The Latest Innovation For Diabetes
The tour organized by Movi SpA, a leading distributor of pioneering diagnostic and therapeutic solutions in the field of diabetes, featured a series of events dedicated to healthcare professionals (with stops in Milan on 02/26/24, Bologna on 02/27/24, and Rome on 02/28/29/24) for the launch of an innovative integrated diabetes management system consisting of the Control-IQ technology pump and the Dexcom G7 sensor.
The round of presentation events focused mainly on illustrating the system’s unique features and discussing its potential positive impact on the daily lives of people undergoing insulin treatment. The presence of multiple legs in different cities across the country made it possible to engage a broader audience and at the same time to establish a network at the local level, which is useful for the exchange of knowledge, experience, and specific issues that meet the needs of professionals dealing with diabetes.
The launch of this new technology on the Italian market is an extremely important event, because the Tandem t:slim X2 pump with Control-IQ technology was the first AHCL (Advanced Hybrid Closed Loop) system to integrate with Dexcom G7, the “Best in Class” sensor on the market.
This state-of-the-art medical device, launched by the Italian company Movi SpA, consists of a pump (Tandem t:slim X2 with Control-IQ technology), associated with a continuous blood glucose monitoring sensor (Dexcom G7) and a predictive control algorithm that automates and customizes insulin delivery based on data from the sensor, responding to the specific needs of each person. This approach provides greater flexibility, autonomy, and quality of life for the user.
Starting with careful listening and a detailed needs analysis, the system was developed to truly meet the real needs of both physician and patient. Among the main benefits of this new technology are greater simplicity in diabetes management, increased reliability of the device, improved quality of life, increased safety in the delivery of glycemic data, and overall optimization of glycemic compensation.
With this innovative device, people with diabetes will be able to achieve a significant improvement in their quality of life, as well as greater simplicity of therapy management by the clinician.
https://www.tecnomedicina.it/movi-presenta-lultima-innovazione-per-il-diabete/